{"version":"1.0","provider_name":"Adacyte","provider_url":"https:\/\/www.adacyte.com\/es\/","author_name":"Adacyte","author_url":"https:\/\/www.adacyte.com\/es\/author\/adacyte\/","title":"El reto del tratamiento de ni\u00f1os con colitis ulcerosa: cuando el equilibrio entre eficacia y seguridad cobra especial relevancia. - Adacyte","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"LZQLKCpRwl\"><a href=\"https:\/\/www.adacyte.com\/es\/gma-pediatria\/\">El reto del tratamiento de ni\u00f1os con colitis ulcerosa: cuando el equilibrio entre eficacia y seguridad cobra especial relevancia.<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.adacyte.com\/es\/gma-pediatria\/embed\/#?secret=LZQLKCpRwl\" width=\"600\" height=\"338\" title=\"\u00abEl reto del tratamiento de ni\u00f1os con colitis ulcerosa: cuando el equilibrio entre eficacia y seguridad cobra especial relevancia.\u00bb \u2014 Adacyte\" data-secret=\"LZQLKCpRwl\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.adacyte.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Actualmente, el doctor Mart\u00edn de Carpi est\u00e1 liderando el estudio GUITART: Granulocyte and monocyte\/macrophage apheresis added to infliximab in paediatric patients with steroid- refractory ulcerative colitis to asses the efficacy and safety of the combined treatment, una investigaci\u00f3n que trata de evaluar la eficacia de la granulocitaf\u00e9resis (GMA) en la disminuci\u00f3n del riesgo de p\u00e9rdida de respuesta a otros f\u00e1rmacos."}